Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar-Apr;32(2 Suppl 81):165-72.
Epub 2014 Apr 15.

Targeted immunotherapies in systemic sclerosis

Affiliations
  • PMID: 24742451
Review

Targeted immunotherapies in systemic sclerosis

Jérôme Avouac et al. Clin Exp Rheumatol. 2014 Mar-Apr.

Abstract

Systemic sclerosis (SSc) is a heterogeneous systemic disorder characterised by alterations of the microvasculature, disturbances of the immune system and massive deposition of collagen and other matrix substances in connective tissue. Recent genetic studies have underlined the importance of the autoimmune component of the disease. Biologic therapies target molecules involved in the mechanisms of the immune system, such as cytokines (TNF-α, IL-6), immune cells (B cells) or co-stimulation molecules (CTLA4), and are currently used in several autoimmune rheumatic diseases, in particular rheumatoid arthritis. These drugs provide an alternative to the existing treatment methods of disease-modifying anti-rheumatic drugs and other immunosuppressive medications. Since some of the molecules targeted by biologic therapies are known to contribute to fibrosis in vitro or in animal models of experimental fibrosis, and considering that preliminary data are now available regarding the efficacy and safety of targeted immunotherapies in SSc, we aim to report with this review the results obtained in animals and humans for the biotherapies that have already been developed.

PubMed Disclaimer

LinkOut - more resources